uniQure (QURE) News Today $16.98 +1.51 (+9.76%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period uniQure (NASDAQ:QURE) Receives $32.14 Consensus Target Price from AnalystsDecember 18 at 2:41 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel NicolausDecember 18 at 1:42 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Reaches New 12-Month High After Analyst UpgradeDecember 18 at 1:07 AM | americanbankingnews.comUp 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?December 15, 2024 | fool.comuniQure (NASDAQ:QURE) Shares Up 5.2% Following Analyst UpgradeDecember 15, 2024 | americanbankingnews.comLeerink Partnrs Reduces Earnings Estimates for uniQureDecember 15, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Given New $20.00 Price Target at Royal Bank of CanadaDecember 13, 2024 | americanbankingnews.comGuggenheim Reaffirms "Buy" Rating for uniQure (NASDAQ:QURE)December 13, 2024 | americanbankingnews.comLeerink Partners Raises uniQure (NASDAQ:QURE) Price Target to $44.00December 13, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Sees Strong Trading Volume After Analyst UpgradeDecember 13, 2024 | americanbankingnews.com**uniQure Reaches Agreement with FDA on Accelerated Approval Pathway for AMT-130 in Huntington’s Disease**December 12, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Hits New 1-Year High on Analyst UpgradeDecember 12, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Given New $58.00 Price Target at Cantor FitzgeraldDecember 11, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Receives "Buy" Rating from HC WainwrightDecember 11, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Rating Increased to Strong-Buy at Raymond JamesDecember 11, 2024 | americanbankingnews.comuniQure's AMT-130: A Bold Step For Huntington's, But Not Without HurdlesDecember 10, 2024 | seekingalpha.comuniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's DiseaseDecember 10, 2024 | globenewswire.comuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyNovember 21, 2024 | globenewswire.comuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 5, 2024 | globenewswire.comuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSOctober 15, 2024 | globenewswire.comuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseSeptember 23, 2024 | globenewswire.comuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseAugust 15, 2024 | globenewswire.comQURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024August 1, 2024 | investorplace.comuniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateAugust 1, 2024 | globenewswire.comuniQure Announces Closing of Sale of Manufacturing Facility to GenezenJuly 23, 2024 | globenewswire.comWhy Is uniQure (QURE) Stock Up 51% Today?July 9, 2024 | investorplace.comuniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's DiseaseJuly 9, 2024 | globenewswire.comGenezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MAJuly 1, 2024 | prnewswire.comuniQure Announces Sale of Commercial Manufacturing Facility to GenezenJuly 1, 2024 | globenewswire.comuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's DiseaseJune 3, 2024 | globenewswire.comQURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | investorplace.comuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 7, 2024 | globenewswire.comuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressFebruary 28, 2024 | globenewswire.comTrading was temporarily halted for "QURE" at 07:10 AM with a stated reason of "News pending."October 5, 2023 | marketbeat.comuniQure: The AMT-130 ReadoutJuly 17, 2023 | seekingalpha.comMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureMay 22, 2023 | seekingalpha.comuniQure: Financials And Pipeline Signal A Promising Outlook For InvestorsMay 20, 2023 | seekingalpha.comuniQure (NASDAQ:QURE) Director Sells $157,356.00 in StockDecember 4, 2022 | marketbeat.comuniQure (NASDAQ:QURE) Price Target Increased to $57.00 by Analysts at The Goldman Sachs GroupNovember 24, 2022 | marketbeat.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseFebruary 7, 2022 | finance.yahoo.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 5, 2022 | washingtonpost.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | finance.yahoo.comEAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B - Marketscreener.comFebruary 4, 2022 | marketscreener.com5 unique date ideas in NW Arkansas - AxiosFebruary 4, 2022 | axios.comAmazon has a unique inflation problem - ReutersFebruary 4, 2022 | reuters.comBears hope Justin Fields ‘skyrockets’ — but his rookie struggles weren’t unique - Chicago Sun-TimesFebruary 3, 2022 | chicago.suntimes.comTurkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington PostFebruary 3, 2022 | washingtonpost.comUnique soap shop franchise to make N.J. debut - NJ.comFebruary 3, 2022 | nj.comLooking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - ForbesFebruary 2, 2022 | forbes.com Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately. QURE Media Mentions By Week QURE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QURE News Sentiment▼0.190.60▲Average Medical News Sentiment QURE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QURE Articles This Week▼90▲QURE Articles Average Week Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News JANX News EWTX News XENE News MRUS News TWST News ACAD News MOR News VCEL News ZLAB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QURE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts